AI-generated analysis. Always verify with the original filing.
TScan Therapeutics, Inc. reported financial results for Q4 and full year 2025, with revenue of $2.6 million in Q4 and $10.3 million for the year, R&D expenses of $20.0 million in Q4 and $114.2 million for the year, and net loss of $23.0 million in Q4 and $129.8 million for the year. Cash and cash equivalents stood at $152.4 million as of December 31, 2025, sufficient to fund operations into the second half of 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 4, 2026, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth
Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: Exhibit No. Descript
| Metric | Value | Basis |
|---|---|---|
| Revenue | $2.57 | |
| Revenue | $10.33 | |
| Research and Development Expenses | $20.04 | |
| Research and Development Expenses | $114.15 | |
| General and Administrative Expenses | $6.39 | |
| General and Administrative Expenses | $31.99 | |
| Net Loss | $23.00 | |
| Net Loss | $129.80 |